(65 days)
The GE Discovery MI is a PET/CT system for producing attenuation corrected PET images. It is intended to be used by qualified health care professionals for imaging the distribution and localization of any positron-emitting radiopharmaceutical in a patient, for the assessment of metabolic (molecular) and physiologic function in patients, with a wide range of sizes and extent of disease, of all ages.
Discovery MI is intended to image the whole body, head, heart, brain, lung, breast, bone, the gastrointestinal and lymphatic systems, and other organs. The images produced by the system may be used by physicians to aid in radiotherapy treatment planning, therapy guidance and monitoring, and in interventional radiology procedures. The images may also be used for precise functional and anatomical mapping (localization, registration, and fusion).
When used with radiopharmaceuticals approved by the regulatory in the country of use, the raw and image data is an aid in; detection, localization, evaluation, diagnosis, staging, monitoring, and/or follow up, of abnormalities, lesions, tumors, inflammation, infection, organ function, disorders, and/or disease, such as, but not limited to, those in oncology, cardiology, and neurology. Examples of which are:
Cardiology:
- Cardiovascular disease
- Myocardial perfusion
- Myocardial viability
- Cardiac inflammation
- Coronary artery disease
Neurology:
- Epilepsy
- Dementia, such as Alzheimer's disease, Lewy body dementia, Parkinson's disease with dementia, and frontotemporal dementia.
- Movement disorders, such as Parkinson's and Huntington's disease
- Tumors
- Inflammation
- Cerebrovascular disease such as acute stroke, chronic and acute ischemia
- Traumatic Brain Injury (TBI)
Oncology/Cancer:
- Non-Small Cell Lung Cancer
- Small Cell Lung Cancer
- Breast Cancer
- Prostate Cancer
- Hodgkin disease
- Non-Hodgkin lymphoma
- Colorectal Cancer
- Melanoma
Discovery MI is also intended for stand-alone, diagnostic CT imaging in accordance with the stand-alone CT system's cleared indications for use.
The Discovery MI system is a PET/CT diagnostic imaging system combining a GE Positron Emission Tomography (PET) System and a GE Computed Tomography (CT) System.
The PET portion of the system uses a Lutetium-based Scintillator (LBS) detector. Scintillator crystal arrays are attached to Silicon Photo Multipliers (SiPM) to form detector units. The detector units are inherited from the reference device Signa PET/MR. Detector units are attached on a common support to form detector modules. The detector modules are arranged in a ring around the patient positioned inside of the PET gantry for detection of gamma rays generated as a result of PET radiopharmaceuticals injected into the patient.
The PET/CT system uses the full-featured multi-slice diagnostic CT subsystem with PET/CT post processing software to generate a map of the non-uniform attenuation in the patient. This attenuation map is then used for attenuation correction of the PET data. The CT image is also used for localization of the PET image in the patient anatomy by means of fusing the PET and CT images.
The Discovery MI system's major components are the PET gantry/detector, Revolution EVO CT system, patient table, operator console/workspace, computing hardware, power distribution unit, system software, and reconstruction software. The operator console and software provide control of the imaging (i.e. setting and confirming conditions of operation), image acquisition, dose display, reconstruction, viewing, post processing analysis, patient management, networking, and filmina. The system may include respiratory and cardiac gating capabilities, signal analysis and display equipment, patient and equipment supports, components and accessories. In addition to being installed as a complete PET/CT system, the Discovery MI may result from an upgrade to a Revolution EVO- based Discovery PET/CT 710.
The Discovery MI system provides scalable axial coverage for the PET detector. All configurations offer reference adult and pediatric protocols for both hybrid PET/CT and CT applications. The PET 3D data acquisition modes include Static, Gated, Dynamic, and Whole Body scanning. All of which can be acquired with List mode data. The system includes standard PET iterative reconstruction alqorithms. Q.Clear full-convergence, reqularized reconstruction is optionally available. Time of Flight (ToF) may be used for all PET reconstruction types.
The CT system is the commercially available 64-detector row Revolution Evo, which may also be used for stand-alone, diagnostic CT imaging. The CT system's acquisition modes include Axial, Cine, Helical (Volumetric), Cardiac, and Gated, for head, whole body, trauma, cardiac and vascular applications.
This document describes the Discovery MI, a PET/CT diagnostic imaging system. No specific acceptance criteria table or a detailed study proving the device meets acceptance criteria in the sense of a clinical trial for diagnostic performance are provided in the extracted text. The document focuses on demonstrating substantial equivalence to a predicate device, as required for a 510(k) premarket notification.
However, the text does mention non-clinical testing to substantiate product performance and claims, which effectively serve as internal performance criteria:
1. Table of Performance Claims Tested (Non-Clinical) and Device Performance (Implicitly Met):
| Performance Metric/Claim Tested | Reported Device Performance (Implicitly Met for Substantial Equivalence) |
|---|---|
| Sensitivity | Successfully verified and substantiated |
| NECR (Noise Equivalent Count Rate) | Successfully verified and substantiated |
| Resolution | Successfully verified and substantiated |
| Lesion Detectability | Successfully verified and substantiated (included a model observer study) |
2. Sample Size and Data Provenance for Test Set:
- Test Set (Non-Clinical): "a variety of test methods and phantoms appropriate for the performance metric/claim to be tested and evaluated." No specific sample size (e.g., number of phantoms) is provided, and the data is generated through physics and engineering analysis, not from human subjects.
- Data Provenance: Non-clinical (phantom-based, mathematical, and physics analysis). Not applicable for country of origin or retrospective/prospective as it's not human data.
3. Number of Experts and Qualifications for Ground Truth of Test Set:
- Not applicable as the "ground truth" for the non-clinical performance evaluations (sensitivity, NECR, resolution, lesion detectability) would be based on the known physical properties of the phantoms and the expected performance of the system as designed and measured, rather than expert consensus on clinical images.
4. Adjudication Method for Test Set:
- Not applicable, as this was non-clinical phantom testing.
5. Multi-Reader Multi-Case (MRMC) Comparative Effectiveness Study:
- No MRMC comparative effectiveness study involving human readers and AI assistance is mentioned. The document explicitly states: "Given the above information and the type and scope of the changes, particularly that the new system uses PET detector modules from the cleared Signa PET/MR, and that its 510k included numerous clinical images, clinical testing is not required to demonstrate that the Discovery MI is as safe and as effective as the legally marketed predicate and reference devices."
6. Standalone (Algorithm Only) Performance Study:
- The "lesion detectability evaluation included a model observer study." This implies a standalone computational assessment of lesion detection performance, without human readers. No specific metrics (e.g., AUC, sensitivity, specificity) or detailed results from this model observer study are provided.
7. Type of Ground Truth Used (for Non-Clinical Tests):
- For non-clinical performance evaluation, the ground truth was based on the known physical properties of the phantoms and the expected performance derived from mathematical and physics analysis.
8. Sample Size for Training Set:
- Not applicable. The document does not describe the development of an AI algorithm that would typically require a training set. The "model observer study" mentioned for lesion detectability is unlikely to refer to a machine learning training set in this context but rather a computational model used to assess detectability in phantoms.
9. How Ground Truth for Training Set Was Established:
- Not applicable, as there is no mention of a machine learning training set for an AI algorithm.
§ 892.1200 Emission computed tomography system.
(a)
Identification. An emission computed tomography system is a device intended to detect the location and distribution of gamma ray- and positron-emitting radionuclides in the body and produce cross-sectional images through computer reconstruction of the data. This generic type of device may include signal analysis and display equipment, patient and equipment supports, radionuclide anatomical markers, component parts, and accessories.(b)
Classification. Class II.